Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.72 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6722230 | 0.94 | TLR7 (0.77) | TLR7TLR8 | |
| SCHEMBL26981091 | 0.92 | TLR7 (0.74) | TLR7TLR8 | |
| SCHEMBL26981129 | 0.89 | TLR7 (0.65) | TLR7TLR8 | |
| SCHEMBL24732770 | 0.88 | TLR7 (0.66) | TLR7TLR8 | |
| SCHEMBL26981069 | 0.86 | TLR7 (0.73) | TLR7TLR8 | |
| SCHEMBL29136648 | 0.85 | TLR7 (0.62) | TLR7TLR8 | |
| SCHEMBL15703349 | 0.84 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL13968009 | 0.83 | TLR7 (0.90) | TLR7TLR8 | |
| SCHEMBL4127474 | 0.82 | TLR7 (0.79) | TLR7TLR8 | |
| SCHEMBL8811709 | 0.82 | TLR7 (0.79) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-06-13 | — | — | US | disclosed |
| EP-4301417-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | The Research Foundation for The State University of New York (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117355341-A | TLR7 and TLR8 agonists for the treatment of cancer and/or infectious diseases | 纽约州立大学研究基金会 | 2024-01-05 | — | — | CN | disclosed |
| WO-2022187809-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | TLR7, TLR8, TLR9 | TLR7 1/4885TLR8 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.